Meta–analysis of right versus left (studies with KRAS mutated patients) stratified by type of treatment

Author	logHR	logHR (SE)	95% CI	Hazard ratio	HR	Weight (fixed)	Weight (random)
Subgroup Treatment = Chemotherapy + anti–EGFR							
PRIME	0.16	0.1629	[0.85; 1.61]		1.17	10.1%	10.1%
PEAK	0.81	0.4831	[0.87; 5.77]		2.24	1.1%	1.9%
20050181	−0.17	0.1445	[0.63; 1.11]		0.84	12.8%	11.4%
AIO KRK0104	0.26	0.3153	[0.70; 2.41]		1.30	2.7%	4.1%
CAIRO–3	0.27	0.1494	[0.98; 1.76]		1.31	12.0%	11.1%
Fixed effect model			[0.95; 1.31]		1.12	38.7%	––
Random effects model			[0.91; 1.47]		1.15	––	38.7%
Heterogeneity: $\tau^2 = 0.0314$, $\chi_4^2 = 7.42$ ($p = 0.12$)							
Subgroup Treatment = Chemotherapy + anti–VEGF							
PEAK	1.03	0.4992	[1.05; 7.45]		2.80	1.1%	1.8%
TRIBE	0.17	0.1692	[0.85; 1.66]		1.19	9.3%	9.7%
AIO KRK0207	0.06	0.1396	[0.81; 1.39]		1.06	13.7%	11.8%
Fixed effect model			[0.94; 1.42]		1.16	24.1%	––
Random effects model			[0.81; 2.07]		1.30	––	23.4%
Heterogeneity: $\tau^2 = 0.1123$, $\chi_2^2 = 3.56$ ($p = 0.17$)							
Subgroup Treatment = Chemotherapy alone							
PRIME	0.09	0.1538	[0.81; 1.47]		1.09	11.3%	10.8%
20050181	0.38	0.1497	[1.09; 1.96]		1.46	11.9%	11.1%
Kamran	0.49	0.2213	[1.06; 2.52]		1.63	5.5%	7.0%
Fixed effect model			[1.10; 1.61]		1.33	28.7%	––
Random effects model			[1.06; 1.69]		1.34	––	28.8%
Heterogeneity: $\tau^2 = 0.0128$, $\chi_2^2 = 2.91$ ($p = 0.23$)							
Subgroup Treatment = Mixed therapies							
OPTIMOX3 DREAM	0.44	0.1780	[1.10; 2.21]		1.56	8.4%	9.2%
Fixed effect model			[1.10; 2.21]		1.56	8.4%	––
Random effects model			[1.10; 2.21]		1.56	––	9.2%
Heterogeneity: not applicable							
Fixed effect model			**[1.10; 1.35]**		**1.22**	**100.0%**	**––**
Random effects model			**[1.09; 1.43]**		**1.25**	**––**	**100.0%**
Prediction interval			**[0.86; 1.81]**				

Heterogeneity: $\tau^2 = 0.0228$, $\chi_{11}^2 = 17.99$ ($p = 0.08$)

Residual heterogeneity: $\chi_8^2 = 13.88$ ($p = 0.08$)

Hazard ratio scale: 0.2 0.5 1 2 5